The published data is based on information submitted by laboratories, doctors and hospitals. It refers to the new reports we received and reviewed. The figures might therefore deviate from those communicated by the cantons.
Epidemiological course see here
Coronavirus: Next phase of reopening on 19 April
Bern, 14.04.2021 - The Federal Council is continuing its strategy of taking cautious, gradual steps towards reopening. At its meeting on 14 April, it decided on further reopening measures. From Monday, 19 April, it will again be possible to hold events with audiences and spectators subject to restrictions, for example at sports stadiums, cinemas, theatres and concert venues. Indoor sports and cultural activities will also be allowed, as well as certain matches and competitions. Restaurants will be able to reopen outside seating areas. Although the situation remains precarious, the Federal Council deems the risk associated with these reopening steps to be acceptable. Read more here
Why manufacturing Covid vaccines at scale is hard
By Anthony King - 23 March 2021
The first Covid-19 vaccine candidate went into the arms of volunteers in Seattle in March 2020. It was an mRNA vaccine from Moderna. The mRNA candidate from BioNTech and Pfizer followed in April. By December 2020, these two had become the first vaccines to be approved by the US Food and Drug Administration (FDA). Hot on their heels are rivals based on adenovirus vectors from AstraZeneca and Johnson & Johnson, as well as Sputnik V from Russia.
Early successes in developing vaccines by upstarts like Moderna and BioNTech papered over the struggles of vaccine heavyweights like Merck, GSK and Sanofi. But those companies that have surmounted the challenges of development now face the next phase: manufacturing doses on an enormous scale. And as Matt Hancock, the UK’s health secretary, told the House of Commons on 18 March ‘the process of manufacturing vaccines is complicated, and subject to unpredictability’. Read more here